Browsing by Author "Ahmed E. Abdel Moneim"

Now showing 1 - 2 of 2

Cinnamic acid Attenuates Cisplatin-Induced Hepatotoxicity and Nephrotoxicity
(National Academy of science, 2016-01-06) Amany A. Tohamy; Ahmed M. Aref; Ahmed E. Abdel Moneim; Romissaa H. Sayed
We investigated the effects of cinnamic acid (CA, 20 mg/kg body weight) on cisplatin (CP)-induced hepto and nephrotoxicity in mice. CP (5 mg/kg bwt) was injected intraperitoneally and CA was given by gastric gavage for 5 days pre- and post-CP injection. After 5 days of CP injection, CP-induced injuries of the hepatic and renal tissues which were evidenced (i) histopathological damage of the hepatic and renal tissues, (ii) as increases in liver and kidney function parameters, (iii) as increases in lipid peroxidation and nitric oxide, and (iv) as decrease in glutathione content. In contrast, the oral administration of CA concurrently to CP intoxicated mice brought back lipid peroxidation, nitric oxide, glutathione levels to near normalcy. Moreover, the histological observations evidenced that CA effectively rescues the liver and kidney from CP mediated oxidative damage. Therefore, cinnamic acid can be considered a potential candidate for protection of hepato-and nephrotoxicity induced by cisplatin.
Evaluation of Vincamine Loaded with Silver Nanoparticles as a New Potential Therapeutic Agent Against Ehrlich’s Solid Carcinoma in Mice
(Multidisciplinary Digital Publishing Institute (MDPI), 2024-11-01) Naief Dahran; Mohamed S. Othman; Mohamed E. Ghoniem; Mai A. Samak; Mohamed T. Elabbasy; Sofian T. Obeidat; Ghada M. Aleid; Shimaa Abo Elnaga; Azza M. Khaled; Aya A. Altaleb; Ahmed E. Abdel Moneim
Vincamine, a monoterpenoid indole alkaloid with vasodilatory properties, is extracted from the leaves of Vinca minor. The present study aimed to determine the potential anticancer effects of vincamine loaded in silver nanoparticles (VCN-AgNPs) in mice with Ehrlich solid carcinoma (ESC). After tumor transplantation, the mice were divided into five groups: ESC, ESC+Cisplatin (CPN; 5 mg/kg), ESC+VCN (40 mg/kg), ESC+AgNPs (6 mg/kg), and ESC+VCN-AgNPs (20 mg/kg). The administration of VCN-AgNPs to ESC-bearing mice improved their survival rate and reduced their body weight, tumor size, and tumor weight compared to the ESC group. Furthermore, VCN-AgNPs intensified oxidative stress in tumor tissues, as evidenced by elevated levels of lipid peroxidation (LPO) and nitric oxide (NO), along with a reduction in the levels of the antioxidants investigated (GSH, GPx, GR, SOD, CAT, and TAC). Furthermore, VCN-AgNPs increased the apoptotic proteins Bax and caspase-3, decreased the anti-apoptotic protein (Bcl-2), increased the inflammatory markers TNF-α and IL-1β, and inhibited angiogenesis by lowering VEGF levels in tumor tissues, all of which led to apoptosis. Furthermore, histopathological studies showed that VCN-AgNPs suppressed the progression of Ehrlich carcinoma and induced the formation of clusters of necrotic and fragmented tumor cells. VCN-AgNPs possess cytotoxic and genotoxic effects against ESC because of their pro-oxidant, pro-apoptotic, pro-inflammatory, and antiangiogenic effects. Additionally, the combination of VCN-AgNPs was more effective and safer than chemically synthesized AgNPs, as indicated by an increase in the lifespan of animals and the total tumor inhibition index.